NMRA DEADLINE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the Firm – NMRA

Core Viewpoint - Rosen Law Firm is urging investors of Neumora Therapeutics, Inc. to secure legal counsel before the April 7, 2025 deadline for a securities class action related to the company's IPO in September 2023 [1][2]. Group 1: Legal Action Details - Investors who purchased Neumora common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by April 7, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a proven track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that the Offering Documents contained false or misleading statements, including the necessity for Neumora to amend trial criteria to justify its Phase Three Program [5]. - It is claimed that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [5].